
Existing levodopa therapies for Parkinson’s disease often provide inadequate symptom control after prolonged treatment. This study assessed the cost-effectiveness of an extended-release carbidopa-levodopa formulation (IPX066).
Existing levodopa therapies for Parkinson’s disease often provide inadequate symptom control after prolonged treatment. This study assessed the cost-effectiveness of an extended-release carbidopa-levodopa formulation (IPX066).
Published: June 12th 2025 | Updated: June 16th 2025
Published: June 10th 2025 | Updated: June 12th 2025
Published: June 2nd 2025 | Updated: June 11th 2025
Published: June 3rd 2025 | Updated: June 11th 2025
Published: May 30th 2025 | Updated: June 5th 2025
Published: April 18th 2025 | Updated: April 21st 2025